MX2019004018A - Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica. - Google Patents

Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.

Info

Publication number
MX2019004018A
MX2019004018A MX2019004018A MX2019004018A MX2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A MX 2019004018 A MX2019004018 A MX 2019004018A
Authority
MX
Mexico
Prior art keywords
treatment
fiibrosis
cystic
substituted pyrrolidines
methods
Prior art date
Application number
MX2019004018A
Other languages
English (en)
Inventor
A Gfesser Gregory
J Scanio Marc
R Kym Philip
Bogdan Andrew
Liu Bo
Desroy Nicolas
R Koenig John
C Yeung Ming
J Altenbach Robert
N Greszler Stephen
De Lemos Elsa
Duthion Béranger
Gaëtan Housseman Christopher
Wang Xueqing
Couty Sylvain
Searle Xenia
Zhao Gang
Original Assignee
Abbvie Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl filed Critical Abbvie Sarl
Publication of MX2019004018A publication Critical patent/MX2019004018A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención desvela compuestos de formula (I) Ver formula: En donde R1, R2, R2A, R3, R3A, R4 Y R5 son como se definen en el presente documento. La presente invención se refiere a compuestos y su uso en el tratamiento de la fibrosis quística, métodos para su producción, composiciones farmacéuticas que los contienen y métodos de tratamiento de la fibrosis quística administrando un compuesto de la invención.
MX2019004018A 2016-10-07 2017-10-06 Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica. MX2019004018A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662405598P 2016-10-07 2016-10-07
PCT/IB2017/056196 WO2018065962A1 (en) 2016-10-07 2017-10-06 Substituted pyrrolidines and their use in the treatment of cystic fiibrosis

Publications (1)

Publication Number Publication Date
MX2019004018A true MX2019004018A (es) 2019-11-12

Family

ID=60268420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004018A MX2019004018A (es) 2016-10-07 2017-10-06 Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.

Country Status (9)

Country Link
US (1) US9981910B2 (es)
EP (1) EP3523293B1 (es)
JP (1) JP2019537564A (es)
CN (1) CN110036009A (es)
AU (1) AU2017339249A1 (es)
BR (1) BR112019007039A2 (es)
CA (1) CA3039659A1 (es)
MX (1) MX2019004018A (es)
WO (1) WO2018065962A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
EP3519401B1 (en) 2016-09-30 2021-09-29 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IL277491B (en) 2016-12-09 2022-08-01 Vertex Pharma Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MD3752510T2 (ro) 2018-02-15 2023-06-30 Vertex Pharma Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US20220089592A1 (en) 2019-01-18 2022-03-24 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US20220211692A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
ME02970B (me) 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
HUE025553T2 (en) 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
WO2009003009A1 (en) * 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
EP2231671B1 (en) 2007-12-13 2013-04-24 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20110074916A (ko) 2008-10-23 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 Ｎ-(4-(7-아자비시클로［2.2.1］헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태
EP2382197B1 (en) * 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
BR112013007907A2 (pt) 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
ES2716723T3 (es) 2011-09-20 2019-06-14 Univ North Carolina Chapel Hill Regulación de los canales de sodio por las proteínas PLUNC
WO2014180562A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
SG11201600891UA (en) 2013-08-08 2016-03-30 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
KR102520483B1 (ko) 2014-10-02 2023-04-12 다우 글로벌 테크놀로지스 엘엘씨 양호한 난연성을 갖는 고주파 용접가능한 에틸렌계 폴리머 조성물
SG11201703391VA (en) * 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
BR112017009194A2 (pt) 2014-10-31 2017-12-26 Abbvie Sarl tetra-hidropiranos substituídos e método de uso
JP2018516932A (ja) 2015-06-02 2018-06-28 アッヴィ・エス・ア・エール・エル 置換ピリジンおよび使用方法
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
BR112018007145A2 (pt) 2015-10-09 2018-11-06 AbbVie S.à.r.l. ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
US9873541B2 (en) 2015-12-24 2018-01-23 Connecticut Container Corp. Rapid assembling container

Also Published As

Publication number Publication date
JP2019537564A (ja) 2019-12-26
US20180099931A1 (en) 2018-04-12
WO2018065962A1 (en) 2018-04-12
BR112019007039A2 (pt) 2019-07-16
CN110036009A (zh) 2019-07-19
EP3523293B1 (en) 2021-06-16
CA3039659A1 (en) 2018-04-12
AU2017339249A1 (en) 2019-05-02
US9981910B2 (en) 2018-05-29
EP3523293A1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
MX2019004018A (es) Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.
MX2019004019A (es) Pirrolidinas sustituidas como moduladores cftr.
PH12018502534A1 (en) Heteroaryl substituted pyridines and methods of use
PH12017502201A1 (en) Substituted pyridines and method of use
PH12020500509A1 (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
SA518392049B1 (ar) مشتقات أمونيوم جديدة، عملية لتحضيرها وتركيبات صيدلانية تحتوي عليها
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
PH12018502515A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
PH12018500061A1 (en) Oxysterols and methods of use thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GEP20207058B (en) Imidazopyrazinones as pde1 inhibitors
AU2018253590A1 (en) Imidazopyridazine compounds
MX2020005079A (es) Derivados de aminotiazol utiles como agentes antiviricos.
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.